Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 17, 2008 - Issue 7
Submit an article Journal homepage
106
Views
7
CrossRef citations to date
0
Altmetric
Review

Therapeutic options for patients with clonal and idiopathic hypereosinophia

Alfonso Quintás-Cardama The University of Texas MD Anderson Cancer Center, Department of Leukemia, Unit 428, 1515 Holcombe Blvd, Houston, TX 77030, USA +1 713 792 0077; +1 713 794 4297; [email protected]
, MD &
Jorge Cortes The University of Texas MD Anderson Cancer Center, Department of Leukemia, Unit 428, 1515 Holcombe Blvd, Houston, TX 77030, USA +1 713 792 0077; +1 713 794 4297; [email protected]
, MD
Pages 1039-1050 | Published online: 12 Jun 2008

Bibliography

  • Hardy WR, Anderson RE. The hypereosinophilic syndromes. Ann Intern Med 1968;68:1220-9
  • Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood 1994;83:2759-79
  • Cools J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201-14
  • Fauci AS, et al. NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med 1982;97:78-92
  • Yoo TJ, et al. Evolution to eosinophilic leukemia with a t(5:11) translocation in a patient with idiopathic hypereosinophilic syndrome. Cancer Genet Cytogenet 1984;11:389-94
  • Needleman SW, et al. Hypereosinophilic syndrome with evolution to myeloproliferative disorder: temporal relationship to loss of Y chromosome and c-N-ras activation. Hematol Pathol 1990;4:149-55
  • Chang HW, et al. Clonality of isolated eosinophils in the hypereosinophilic syndrome. Blood 1999;93:1651-7
  • Higuchi W, et al. Hypereosinophilic syndrome terminating in acute myelogenous leukemia. Acta Haematol 1993;90:165-6
  • Luppi M, et al. Clonal nature of hypereosinophilic syndrome. Blood 1994;84:349-50
  • Cogan E, et al. Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. N Engl J Med 1994;330:535-8
  • Brugnoni D, et al. A case of hypereosinophilic syndrome is associated with the expansion of a CD3-CD4+ T-cell population able to secrete large amounts of interleukin-5. Blood 1996;87(4):1416-22
  • Simon HU, et al. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 1999;341(15):1112-20
  • Roufosse F, et al. Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome. Br J Haematol 2000;109(3):540-8
  • Cilloni D, et al. WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia. Leukemia 2007;21(7):1442-50
  • Wilkins HJ, et al. Hypereosinophilic syndrome: an update. Am J Hematol 2005;80(2):148-57
  • Tefferi A. Modern diagnosis and treatment of primary eosinophilia. Acta Haematol 2005;114(1):52-60
  • Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22(1):14-22
  • Lefebvre C, et al. Prognostic factors of hypereosinophilic syndrome. Study of 40 cases. Ann Med Interne (Paris) 1989;140(4):253-7
  • Spry CJ et al. Clinical features of fifteen patients with the hypereosinophilic syndrome. Q J Med 1983;52(205):1-22
  • Dahabreh IJ, et al. Management of hypereosinophilic syndrome: a prospective study in the era of molecular genetics. Medicine (Baltimore) 2007;86(6):344-54
  • Pitini V, et al. Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes. Blood 2003;102(9):3456-7; author reply 3457
  • Parrillo JE, Fauci AS, Wolff SM. Therapy of the hypereosinophilic syndrome. Ann Intern Med 1978;89(2):167-72
  • Roufosse FE, Goldman M, Cogan E. Hypereosinophilic syndromes. Orphanet J Rare Dis 2007;2:37
  • Butterfield JH, Gleich GJ. Interferon-alpha treatment of six patients with the idiopathic hypereosinophilic syndrome. Ann Intern Med 1994;121(9):648-53
  • Zielinski RM, Lawrence WD. Interferon-alpha for the hypereosinophilic syndrome. Ann Intern Med 1990;113(9):716-8
  • Murphy PT, et al. Alfa-interferon in a case of hypereosinophilic syndrome. Br J Haematol 1990;75(4):619-20
  • Baratta L, et al. Favorable response to high-dose interferon-alpha in idiopathic hypereosinophilic syndrome with restrictive cardiomyopathy – case report and literature review. Angiology 2002;53(4):465-70
  • Ceretelli S, Capochiani E, Petrini M. Interferon-alpha in the idiopathic hypereosinophilic syndrome: consideration of five cases. Ann Hematol 1998;77(4):161-4
  • Luciano L, et al. AlphaIFN-induced hematologic and cytogenetic remission in chronic eosinophilic leukemia with t(1;5). Haematologica 1999;84(7):651-3
  • Kioke T, Nakamura Y, Enokihara H. Interferon-alpha inhibits interleukin-5 and granulocyte-macrophage colony stimulating factor production by lymphocytes and suppresses eosinophil colony formation from bone marrow progenitor cells. Dokkyo J Med Sci 1998;25:45-52
  • Aldebert D, et al. Eosinophils express a functional receptor for interferon alpha: inhibitory role of interferon alpha on the release of mediators. Blood 1996;87(6):2354-60
  • Schandene L, et al. Interferon-alpha upregulates both interleukin-10 and interferon-gamma production by human CD4+ T cells. Blood 1997;89(3):1110-1
  • Krishnaswamy G, et al. Lymphoblastoid interferon-alpha inhibits T cell proliferation and expression of eosinophil-activating cytokines. J Interferon Cytokine Res 1996;16(10):819-27
  • Bletry O, Papo T. Interferons. Interferons alpha and gamma: indications in systemic diseases. Ann Med Interne (Paris) 1993;144(8):557-62
  • Coutant G, et al. Treatment of hypereosinophilic syndromes of myeloproliferative expression with the combination of hydroxyurea and interferon alpha. Apropos of 7 cases. Ann Med Interne (Paris) 1993;144(4):243-50
  • Demiroglu H, Dundar S. Combination of interferon-alpha and hydroxyurea in the treatment of idiopathic hypereosinophilic syndrome. Br J Haematol 1997;97(4):928-30
  • Cofrancesco E, et al. Response to vincristine treatment in a case of idiopathic hypereosinophilic syndrome with multiple clinical manifestations. Acta Haematol 1984;72(1):21-5
  • Marshall GM, White L. Effective therapy for a severe case of the idiopathic hypereosinophilic syndrome. Am J Pediatr Hematol Oncol 1989;11(2):178-83
  • Sakamoto K, et al. Prolonged clinical response to vincristine treatment in two patients with idiopathic hypereosinophilic syndrome. Am J Pediatr Hematol Oncol 1992;14(4):348-51
  • Ueno NT, et al. 2-Chlorodeoxyadenosine therapy for idiopathic hypereosinophilic syndrome. Leukemia 1997;11(8):1386-90
  • Smit AJ, van Essen LH, de Vries EG. Successful long-term control of idiopathic hypereosinophilic syndrome with etoposide. Cancer 1991;67(11):2826-7
  • Zabel P, Schlaak M. Cyclosporin for hypereosinophilic syndrome. Ann Hematol 1991;62(6):230-1
  • Nadarajah S, et al. Treatment of hypereosinophilic syndrome in a child using cyclosporine: implication for a primary T-cell abnormality. Pediatrics 1997;99(4):630-3
  • Archimbaud E, et al. Hypereosinophilic syndrome with multiple organ dysfunction treated by allogeneic bone marrow transplantation. Am J Hematol 1988;27(4):302-3
  • Sigmund DA, Flessa HC. Hypereosinophilic syndrome: successful allogeneic bone marrow transplantation. Bone Marrow Transplant 1995;15(4):647-8
  • Esteva-Lorenzo FJ, et al. Allogeneic bone marrow transplantation in a patient with hypereosinophilic syndrome. Am J Hematol 1996;51(2):164-5
  • Fukushima T, et al. Successful bone marrow transplantation for idiopathic hypereosinophilic syndrome. Br J Haematol 1995;90(1):213-5
  • Sadoun A, et al. Allogeneic bone marrow transplantation for hypereosinophilic syndrome with advanced myelofibrosis. Bone Marrow Transplant 1997;19(7):741-3
  • Vazquez L, et al. Allogeneic peripheral blood cell transplantation for hypereosinophilic syndrome with myelofibrosis. Bone Marrow Transplant 2000;25(2):217-8
  • Juvonen E, et al. Allogeneic blood stem cell transplantation following non-myeloablative conditioning for hypereosinophilic syndrome. Bone Marrow Transplant 2002;29(5):457-8
  • Cooper MA, et al. Hypereosinophilic syndrome: long-term remission following allogeneic stem cell transplant in spite of transient eosinophilia post-transplant. Am J Hematol 2005;78(1):33-6
  • Ueno NT, et al. Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome. Br J Haematol 2002;119(1):131-4
  • Halaburda K, et al. Allogeneic bone marrow transplantation for hypereosinophilic syndrome: long-term follow-up with eradication of FIP1L1-PDGFRA fusion transcript. Bone Marrow Transplant 2006;38(4):319-20
  • Schaller JL, Burkland GA. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. MedGenMed 2001;3(5):9
  • Pardanani A, et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 2003;101(9):3391-7
  • Gleich GJ, et al. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 2002;359(9317):1577-8
  • Ault P, et al. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res 2002;26(9):881-4
  • Nolasco I, Carvalho S, Parreira A, et al. Rapid and complete response to imatinib mesylate (STI-571) in a patient with idiopathic hypereosinophilia [abstract 346b]. Blood 2002;100
  • Cortes J, et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood 2003;101(12):4714-6
  • Gorre ME, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293(5531):876-80
  • Klion AD, et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 2004;103(2):473-8
  • Klion AD, et al. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing. Blood 2007;110(10):3552-6
  • Helbig G, et al. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients. Br J Haematol 2008;141(2):200-4
  • Gotlib J. Molecular classification and pathogenesis of eosinophilic disorders: 2005 update. Acta Haematol 2005;114(1):7-25
  • Griffin JH, et al. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci USA 2003;100(13):7830-5
  • Stover EH, et al. Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent. Proc Natl Acad Sci USA 2006;103(21):8078-83
  • Score J, et al. Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia 2006;20(5):827-32
  • Walz C, et al. Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene. Genes Chromosomes Cancer 2006;45(10):950-6
  • Wilkinson K, et al. Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. Blood 2003;102(12):4187-90
  • David M, et al. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood 2007;109(1):61-4
  • Pardanani A, Tefferi A. Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders. Leuk Res 2004;28(Suppl 1):S47-52
  • Metzgeroth G, et al. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia 2007;21(6):1183-8
  • Sato Y, et al. Measurement of serum concentrations of cardiac troponin T in patients with hypereosinophilic syndrome: a sensitive non-invasive marker of cardiac disorder. Intern Med 2000;39(4):350
  • Weisberg E, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7(2):129-41
  • Manley PW, Cowan-Jacob SW, Mestan J. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. Biochim Biophys Acta 2005;1754(1-2):3-13
  • O'Hare T, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65(11):4500-5
  • Verstovsek S, et al. Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells. Leuk Res 2006
  • Stover EH, et al. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood 2005;106(9):3206-13
  • Cools J, et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease. Cancer Cell 2003;3(5):459-69
  • von Bubnoff N, et al. The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib). Blood 2006;107(12):4970-1; author reply 4972
  • Kantarjian H, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354(24):2542-51
  • Le Coutre P, Hochhaus A, Heim D, et al. A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to patients with hypereosinophilic syndrome (HES) [abstract 4912]. Blood 2006;108(11)
  • Lombardo LJ, et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47(27):6658-61
  • Schittenhelm MM, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006;66(1):473-81
  • Talpaz M, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354(24):2531-41
  • Verstovsek S, Tefferi A, Cortes J, et al. Phase II study of dasatinib (SPRYCEL) in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis [abstract 3551]. Blood 2007;110(11)
  • Strumberg D, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23(5):965-72
  • Lierman E, et al. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood 2006;108(4):1374-6
  • Pan J, Quintas-Cardama A, Kantarjian HM, et al. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation. Blood 2007;109(1):315-22
  • Pan J, et al. The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1. Leukemia 2007;21(7):1395-404
  • Fabbro D, et al. PKC412–a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 2000;15(1):17-28
  • Chen J, et al. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci USA 2004;101(40):14479-84
  • Sanderson CJ. Interleukin-5, eosinophils, and disease. Blood 1992;79(12):3101-9
  • Roufosse F, Cogan E, Goldman M. Recent advances in pathogenesis and management of hypereosinophilic syndromes. Allergy 2004;59(7):673-89
  • Klion AD, et al. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood 2004;103(8):2939-41
  • Hart TK, et al. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J Allergy Clin Immunol 2001;108(2):250-7
  • Plotz SG, et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 2003;349(24):2334-9
  • Rothenberg ME, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008;358(12):1215-28
  • Sefcick A, et al. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome. Br J Haematol 2004;124(4):558-9
  • Pitini V, et al. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report. Br J Haematol 2004;127(5):477
  • Quintás-Cardama A, Tefferi A, Cortes J, et al. Alemtuzumab (CAMPATH-1H) is effective therapy for hypereosinophilic syndrome (HES) [abstract 4902]. Blood 2006;109(11)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.